BDX - Becton, Dickinson and Company

NYSE - NYSE Delayed Price. Currency in USD
236.11
+4.84 (+2.09%)
At close: 4:00PM EST

236.11 0.00 (0.00%)
After hours: 4:46PM EST

Stock chart is not supported by your current browser
Previous Close231.27
Open235.09
Bid232.00 x 1000
Ask260.00 x 800
Day's Range232.00 - 237.11
52 Week Range208.62 - 265.87
Volume1,651,400
Avg. Volume1,235,241
Market Cap63.62B
Beta (3Y Monthly)1.32
PE Ratio (TTM)393.52
EPS (TTM)0.60
Earnings DateFeb 5, 2019
Forward Dividend & Yield3.08 (1.36%)
Ex-Dividend Date2018-12-07
1y Target Est265.05
Trade prices are not sourced from all markets
  • Is Becton, Dickinson and Company (NYSE:BDX) Worth US$226 Based On Intrinsic Value?
    Simply Wall St.7 hours ago

    Is Becton, Dickinson and Company (NYSE:BDX) Worth US$226 Based On Intrinsic Value?

    How far off is Becton, Dickinson and Company (NYSE:BDX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock Read More...

  • Here's Why Investors Should Retain athenahealth (ATHN) Stock
    Zacks11 hours ago

    Here's Why Investors Should Retain athenahealth (ATHN) Stock

    athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.

  • Allscripts Selected by Premier for Connected Health Platform
    Zacks11 hours ago

    Allscripts Selected by Premier for Connected Health Platform

    Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.

  • TheStreet.com12 hours ago

    Becton Dickinson Expects First-Quarter Earnings to Beat Wall Street Estimates

    said it expects fiscal first-quarter results above Wall Street's expectations. The multinational medical technology company expects quarterly revenue of $4.16 billion for the first fiscal quarter ended Dec. 31, an increase of 35.1% from the prior year, primarily due to the acquisition of C. R. Bard, the company said. Preliminary earnings per share of $2.70 increased 8.9% from $2.48 the prior year, or 14.9% on a currency-neutral basis.

  • MarketWatch13 hours ago

    Becton Dickinson profit, revenue to rise above expectations

    Becton Dickinson & Co. said it expects to swing to fiscal first-quarter net earnings per share of $2.05, from a loss of 76 cents in the same period a year ago. Excluding non-recurring items, adjusted EPS is expected to rise to $2.70 from $2.48, above the FactSet consensus of $2.59. Revenue is expected to rise 35% to $4.16 billion, topping the FactSet consensus of $4.11 billion. The medical technology company affirmed its 2019 revenue growth outlook of 8.5% to 9.5%, and its adjusted EPS guidance of $12.05 to $12.15. The stock, which was still inactive in premarket trade, has lost 5.6% over the past three months, while the SPDR Health Care Select Sector ETF has declined 5.5% and the S&P 500 has given up 6.9%.

  • PR Newswire14 hours ago

    BD Announces Preliminary Results For 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

    - Preliminary reported revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, preliminary revenues increased 5.2 percent. - As reported, preliminary diluted earnings ...

  • 10 Profit-Rich Stocks for Lean Times
    Investopediayesterday

    10 Profit-Rich Stocks for Lean Times

    Corporate profit margins are under pressure from a variety of forces, but these stocks are bucking the trend.

  • Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
    Zacksyesterday

    Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up

    Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.

  • Here's Why You Should Invest in OPKO Health (OPK) Right Now
    Zacksyesterday

    Here's Why You Should Invest in OPKO Health (OPK) Right Now

    OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.

  • PR Newswire2 days ago

    BD Announces Webcast of Annual Meeting of Shareholders

    FRANKLIN LAKES, N.J. , Jan. 15, 2019 /PRNewswire/ --   BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual ...

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Becton Dickinson and Co.

    # Becton Dickinson and Co ### NYSE:BDX View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for BDX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $14.29 billion over the last one-month into ETFs that hold BDX are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BDX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire9 days ago

    BD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call

    FRANKLIN LAKES, N.J. , Jan. 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference ...

  • GuruFocus.com10 days ago

    52-Week Company Lows

    According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows. The price of Becton, Dickinson and Co. (BDX) shares has declined to close to the 52-week low of $216.99, which is 21.5% off the 52-week high of $265.87. The company has a market cap of $58.47 billion.

  • Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA
    Zacks20 days ago

    Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA

    Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.

  • Stocks down in December for pharma firms in the Triangle
    American City Business Journals21 days ago

    Stocks down in December for pharma firms in the Triangle

    Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.

  • Benzinga21 days ago

    The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 26) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Down In The ...

  • Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
    Zacks22 days ago

    Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

    Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

  • PR Newswire27 days ago

    BD to Present at Investor Healthcare Conferences

    FRANKLIN LAKES, N.J. , Dec. 21, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming ...

  • Tech manufacturer considering Mebane for $176M existing facility expansion
    American City Business Journals28 days ago

    Tech manufacturer considering Mebane for $176M existing facility expansion

    New Jersey-based Becton, Dickinson and Co. (NYSE:BDX) is considering Mebane and two other locations for a $176 million existing facility expansion expected to create 116 jobs with an average salary of $67,759. On Dec. 17, Alamance County Commissioners voted 4-1 on an incentive grant of $2.6 million to lure the company, which manufacturers and sells medical devices, instrument systems and regents. The Mebane City Council has also approved incentives and waived fees totaling $2.64 million.

  • BD Completes Molecular Portfolio for GI Infection With New Viral Panel
    PR Newswire29 days ago

    BD Completes Molecular Portfolio for GI Infection With New Viral Panel

    FRANKLIN LAKES, N.J., Dec. 20, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX™ enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis. The company now offers a broad suite of solutions for the detection of intestinal conditions of bacterial, viral, and parasitic origin, in clinically relevant, targeted panels.

  • Is Now The Time To Look At Buying Becton, Dickinson and Company (NYSE:BDX)?
    Simply Wall St.29 days ago

    Is Now The Time To Look At Buying Becton, Dickinson and Company (NYSE:BDX)?

    Becton, Dickinson and Company (NYSE:BDX) received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to $264.38 at one point, and Read More...

  • How Wall Street Analysts View Medtronic in December
    Market Realistlast month

    How Wall Street Analysts View Medtronic in December

    In November, Medtronic announced that the company would acquire Nutrino Health, a company that specializes in nutrition associated data services, analytics, and technologies. Medtronic’s diabetes segment is expected to improve significantly with the acquisition of Nutrino Health. The acquisition of Nutrino Health will bring together Nutrino Health’s robust food database, expertise in nutrition science and food analysis systems, and Medtronic’s innovative diabetes management resources.

  • Zackslast month

    BD Gets Enterprise Level Cybersecurity Assessment From UL

    BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.